TY - JOUR
T1 - Hyperprolactinemia with aripiprazole
T2 - Understanding the paradox
AU - Saraf, Gayatri
AU - Behere, Rishikesh V.
AU - Venkatasubramanian, Ganesan
AU - Rao, Naren P.
AU - Varambally, Shivarama
AU - Gangadhar, B. N.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.
AB - Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.
UR - https://www.scopus.com/pages/publications/84900790133
UR - https://www.scopus.com/pages/publications/84900790133#tab=citedBy
U2 - 10.1097/MJT.0b013e3182456de7
DO - 10.1097/MJT.0b013e3182456de7
M3 - Article
C2 - 22357167
AN - SCOPUS:84900790133
SN - 1075-2765
VL - 21
SP - e80-e81
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
IS - 3
ER -